ALBIREO PHARMA INC (ALBO) Stock Price, Quote, News and Overview
NASDAQ:ALBO - Nasdaq - US01345P1066 - Common Stock - Currency: USD
ALBO Quote, Performance and Key Statistics
44.15
-0.1 (-0.23%)
The current stock price of ALBO is 44.15 USD. In the past month the price decreased by -1.23%. In the past year, price increased by 66.73%.
ALBO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ALBO
Company Profile
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. The company is headquartered in Boston, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2007-05-11. The firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.
Company Info
ALBIREO PHARMA INC
10 Post Office Square, Suite 502 South
Boston MASSACHUSETTS 02109 US
CEO: Ronald H.W. Cooper
Employees: 130
Company Website: https://albireopharma.com/
Phone: 18574154774.0
ALBIREO PHARMA INC / ALBO FAQ
What is the stock price of ALBIREO PHARMA INC today?
The current stock price of ALBO is 44.15 USD. The price decreased by -0.23% in the last trading session.
What is the ticker symbol for ALBIREO PHARMA INC stock?
The exchange symbol of ALBIREO PHARMA INC is ALBO and it is listed on the Nasdaq exchange.
On which exchange is ALBO stock listed?
ALBO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALBIREO PHARMA INC stock?
13 analysts have analysed ALBO and the average price target is 42.84 USD. This implies a price decrease of -2.97% is expected in the next year compared to the current price of 44.15. Check the ALBIREO PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALBIREO PHARMA INC worth?
ALBIREO PHARMA INC (ALBO) has a market capitalization of 915.89M USD. This makes ALBO a Small Cap stock.
How many employees does ALBIREO PHARMA INC have?
ALBIREO PHARMA INC (ALBO) currently has 130 employees.
What are the support and resistance levels for ALBIREO PHARMA INC (ALBO) stock?
ALBIREO PHARMA INC (ALBO) has a support level at 43.96 and a resistance level at 44.96. Check the full technical report for a detailed analysis of ALBO support and resistance levels.
Is ALBIREO PHARMA INC (ALBO) expected to grow?
The Revenue of ALBIREO PHARMA INC (ALBO) is expected to grow by 69.42% in the next year. Check the estimates tab for more information on the ALBO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALBIREO PHARMA INC (ALBO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALBO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALBO, evaluating the profitability, health, valuation and growth aspects
- ALBIREO PHARMA INC (ALBO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALBIREO PHARMA INC (ALBO) Sales and EPS estimates to see what analysts future expectations are.
- ALBIREO PHARMA INC (ALBO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALBIREO PHARMA INC (ALBO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALBIREO PHARMA INC (ALBO) Stock Chart to make your own analysis
- ALBIREO PHARMA INC (ALBO) Latest news and press-releases to stay up to date.
Does ALBIREO PHARMA INC (ALBO) stock pay dividends?
ALBO does not pay a dividend.
When does ALBIREO PHARMA INC (ALBO) report earnings?
ALBIREO PHARMA INC (ALBO) will report earnings on 2023-05-15.
What is the Price/Earnings (PE) ratio of ALBIREO PHARMA INC (ALBO)?
ALBIREO PHARMA INC (ALBO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.72).
ALBO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALBO. When comparing the yearly performance of all stocks, ALBO is one of the better performing stocks in the market, outperforming 98.27% of all stocks.
ALBO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALBO. The financial health of ALBO is average, but there are quite some concerns on its profitability.
ALBO Financial Highlights
Over the last trailing twelve months ALBO reported a non-GAAP Earnings per Share(EPS) of -6.72. The EPS increased by 10.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ALBO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to ALBO. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -20.91% and a revenue growth 69.42% for ALBO